天美传媒

Triple board-certified in internal medicine, hematology and medical oncology, Dr. Mohamad Cherry is medical director of Hematology at Atlantic Health System Cancer Care. He joined Atlantic Hematology Oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center, bringing years of clinical knowledge and expertise.

With specialty training from some of the nation's most skilled clinicians, Dr. Cherry attained some of his clinical training at the leukemia department at MD Anderson and his fellowship in hematology/oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He performed two residencies - an internal medicine residency at Staten Island University Hospital and a laboratory medicine residency at the American University of Beirut Medical Center in Lebanon. Previously, Dr. Cherry attained his medical degree at Lebanese University and performed his internship at Sacre Coeur Hospital-Lebanese University. He also earned a master of science degree in clinical and translational research from University of Oklahoma College of Public Health.

Dr. Cherry remains on staff as clinical associate professor of hematology/oncology at University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He is also the director of its hematology/oncology fellowship program and co-chairs the Academy of Teaching Scholars Faculty Development, Education and Mentoring Committee. Other administrative roles include co-chair of the leukemia working group at the Sarah Cannon Research Institute Blood Cancer Consortium.

As a principal investigator of multiple clinical trials, Dr. Cherry has performed groundbreaking research in niche areas that include epigenetics and development of new therapeutics in relapsed and refractory blood cancers. He has developed teaching materials and book chapters, and has lectured both nationally and internationally.

Dr. Cherry continues to serves as a mentor and an advisor to fellows, residents and medical students. He contributes to continuing education, public health, and professional development, and has won awards and funding for both his research and his clinical pursuits.

Dr. George received a doctor of medicine from Wake Forest University School of Medicine in 1996. He completed a residency at University of Colorado and a fellowship in hematology and oncology at University of Chicago in 2002. Dr. George is board-certified by the American Board of Internal Medicine- Hematology and the American Board of Internal Medicine- Medical Oncology. He has a special interest in genitourinary cancers and gastrointestinal cancers.

Dr Sekeres has focused on leukemias, and particularly myelodysplastic syndromes and acute myeloid leukemia in older adults, for two decades. He has developed innovative therapies for these cancers; helped define the genetics of leukemia and related blood and bone marrow cancers along with clinical correlates; helped redefine prognostication, including innovative methods using machine learning and artificial intelligence; and helped define the epidemiology and patient reported outcomes in these conditions. He has also chaired the FDA’s Oncologic Drugs Advisory Committee and is an expert on cancer regulatory issues, and is a widely published essayist focused on patient-doctor communication, with 60 essays in The New York Times.

Danielle M. Alm, PharmD, BCPS, BCPPS, is an Associate Professor of Clinical Pharmacy at the Philadelphia College of Pharmacy (PCP). Additionally, she is a Pediatric Clinical Pharmacy Specialist at Children鈥檚 Regional Hospital at Cooper University HealthCare. In this role she practices in general pediatrics as well as pediatric intensive care unit patients. Here, Dr. Alm precepts learners, including introductory and advanced pharmacy practice experience (IPPE) and (APPE) students and a PGY2 Pharmacotherapy Resident.

On campus, Dr. Alm鈥檚 didactic teaching responsibilities include pediatric content taught throughout the curriculum. Pediatric content includes pediatric infectious diseases, pharmacokinetic and pharmacodynamic differences, pediatric enteral and parenteral nutrition, pediatric seizures, multiple sclerosis, drug information and literature evaluation, and hematology and oncology. She also coordinates the pediatric elective. Dr. Alm鈥檚 research interests include student run research, pediatric research focusing on medication safety, pharmacodynamics, and asthma. She is an active member of the Pediatric Pharmacist Association (PPA) where she has served in many different roles.

Terri Parker, MD, is an Assistant Professor of Medicine at the Yale School of Medicine in the section of Hematology. Dr. Parker completed her internal medicine residency at the University of Connecticut followed by a fellowship program in hospice and palliative medicine. She also completed a fellowship in hematology and medical oncology at Yale University School of Medicine.
Dr. Parker serves as the assistant medical director at the Smilow Cancer Hospital Care Center in North Haven that is home to two hematology programs, classical hematology and the multiple myeloma and gammopathies program. She is a member of the protocol review committee (PRC) at the Yale Cancer Center, which is charged with the scientific evaluation of all cancer clinical protocols and amendments proposed at Yale prior to initiation. Dr. Parker currently serves as co-chair of the Multiple Myeloma Committee for ClinicalPath, which presents evidence-based oncology pathways to academic and community practices.
Dr. Parker treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukemia, smoldering multiple myeloma, and Waldenstrom鈥檚 macroglobulinemia. She has experience with clinical trials focused on novel therapies and drug combinations with a goal of advancing the standard of care for patients with AL amyloidosis, newly diagnosed and relapsed refractory multiple myeloma.


Education & Training:
Fellowship- Yale University School of Medicine (2012)
Fellowship- University of Connecticut Health Center (2009)
Residency- University of Connecticut Health Center (2008)
MD- St. George's University School of Medicine Grenada (2005)
BS- University of Pittsburgh (2001)

Honors & Recognition:

2016 David S. Fischer Teaching Award for Outstanding Faculty Teaching and Mentoring of Fellows in Medical Oncology
2006 Letter of Recognition from Evaluation and Promotions Committee at University of Connecticut

Amer Zeidan, MBBS, MHS @Dr_AmerZeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid malignancies Clinical Research Team (CRT), and the director of Continuing Medical Education (CME) at the Hematology division at Yale Cancer Center. Dr. Zeidan completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr. Zeidan specializes in the management of myeloid malignancies especially MDS and acute myeloid leukemia (AML).
The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for myeloid malignancies, with a special focus on targeted therapies and immunotherapy-based approaches. Dr. Zeidan is also active in health outcomes and comparative effectiveness research for blood cancers and their therapies. Dr. Zeidan has and continues to serve as the principal investigator of many investigator-initiated, cooperative group and industry sponsored clinical trials for myeloid malignancies.
Dr. Zeidan also chairs or serves on the steering committees of several large clinical trials of myeloid malignancies. He has served as the vice chair of the Yale Cancer Center Data and Safety Monitoring Committee (YCC DSMC) and currently serves in the independent data and safety monitoring committees of multiple clinical trials. Dr. Zeidan is a member of the MyeloMATCH Precision medicine initiative of the National Cancer Institute (NCI) for both MDS and AML and is very active within the Cancer Therapy Evaluation Program (CTEP) and Early Therapy Clinical Trial Network (ETCTN) in working on early phase clinical trials of novel therapies for myeloid malignancies.
Dr. Zeidan has presented his research in many meetings and has been an invited speaker nationally and internationally. He regularly reviews abstracts for the American Society of Hematology (ASH) annual meetings and chairs meeting sessions. He has been presented on MDS in the ASH Annual highlights meetings in USA and Asia-Pacific as well as the ASH Meeting on Hematologic Malignancies. He is also active within the International Working Group (IWG) of MDS and has previously served on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines panel for MDS.
Dr. Zeidan has received several prestigious awards including the Leukemia and Lymphoma Society Scholar in Clinical Research award, the National Cancer Institute Cancer Clinical Investigator Team Leadership award, the AAMDSIF/Evan’s Foundation-MDS Clinical Research Consortium Fellowship award, the Tito Bastianello Young Investigator Award, the ASCO Young Investigator Award, and multiple other achievement awards. Dr. Zeidan also serves on the editorial board and is a reviewer of several important hematology and oncology journals. He is an author on more than 260 peer-reviewed publications and book chapters.

George Goshua, MD, MSc is an Assistant Professor of Medicine (Hematology) in the Clinician-Scientist Track. He is a Yale-trained, board-certified internist and hematologist, with methodological training in risk and decision science from the Harvard T.H. Chan School of Public Health. Dr. Goshua is the PI of the first quantitative decision analytic modeling laboratory in hematology-oncology in the United States (Goshua Lab). His clinical expertise is in the care of adults with rare hematologic disorders, with a particular focus in immunohematology and thrombosis. His laboratory research employs quantitative decision analytic modeling methods to #1 fill gaps in clinical guidelines, #2 impact health resource allocation and/or #3 inform health policy decisions. This body of original science has been published in journals that include the Annals of Internal Medicine, Blood (inclusive of a #1 globally trending manuscript), The Lancet Haematology (the journal's #1 most cited original research), The Lancet Regional Health, Blood Advances, American Journal of Hematology (2021 AJH Young Investigator Award, 2022 AJH YIA Finalist), Science Immunology, Chest, and Clinical Infectious Diseases. Beyond research recognitions awarded by the leading hematology societies, Dr. Goshua's invited service at the interface of decision science and clinical medicine includes the 1. American Society of Hematology Patient Decision Aid Steering Group, 2. Institute for Clinical and Economic Review's Independent Appraisal Committee, and 3. Editorial Board at the Annals of Internal Medicine, with an expert focus in health economics.

Shail Maingi, MD (she/her) is a medical oncologist, hematologist, and palliative care physician at the Dana-Farber Cancer Institute South Shore location. In addition to seeing patients with solid tumors and blood diseases, she is the inaugural DFCI Network Health Equity and Inclusion Liaison. Dr. Maingi has been a health equity advocate and clinical researcher for years, with a focus on health care disparities in oncology and end-of-life settings, particularly for sexual and gender minority people and with a focus on intersectionality.  She is currently part of the scientific program committee for the American Society of Clinical Oncology (ASCO) annual conference and serves on ASCO’s Diversity and Inclusion Committee, Practice Health Task Force, and as the co-chair of their Sexual and Gender Minority Task Force. Dr. Maingi was also the founding chair of the American Academy of Hospice and Palliative Medicine’s LGBTQ Special Interest Group. She serves on the GLMA: Health Professionals Advancing LGBTQ Equality board and heads their Racial Justice Task Force, after serving as their VP for the Lesbian Health Fund for 6 years. 

Dr. Jayachandran specializes in Breast Medical Oncology. She is an Assistant Professor of Clinical Medicine at Keck and also serves as the Director of Breast Medical Oncology and Genomics at the LAC+USC Medical Center. She graduated from Stanford University and the University of Michigan Medical School before completing her residency in Internal Medicine at UCSF Fresno and fellowship in Hematology/Oncology at USC. She is active in research with a focus on clinical trials, translational studies, biomarkers, and improving access to care. She enjoys teaching fellows, residents, and medical students.

Dr. Jorge Nieva graduated from the University of California, Irvine College of Medicine in 1997, trained in internal medicine at University of California, San Diego and in oncology and hematology at the Scripps Clinic. In 2003 he joined the faculty of the Scripps Research Institute and the medical staff of the Scripps Clinic in La Jolla, CA. While at Scripps, Dr. Nieva pioneered new technology for the detection of cancer cells in the peripheral blood and discoveries related to the fundamental mechanisms of the immune system.
Dr. Nieva was recruited to the Billings Clinic in Montana in 2007 where he served as department chair and was a program leader who established the multidisciplinary lung cancer and head/neck cancer clinics at the cancer center. While in Billings, Dr. Nieva led efforts to establish a research program in virus-delivered cancer gene therapy and immunotherapy. His teams were awarded certificates for excellence in the conduct of cancer clinical trials from the National Cancer Institute and the American Society of Clinical Oncology. Dr. Nieva returned to California, joining the faculty of the Keck School of Medicine in 2014.

Dr. El-Khoueiry completed his medical degree, residency in internal medicine and fellowship in hematology and oncology at the Keck School of Medicine of the University of Southern California. He is currently associate professor of clinical medicine in the Division of Medical Oncology, a member of the Gastrointestinal Cancers Program and director of the phase I drug development clinical program. He has been the medical director of the Clinical Investigations Support Office at the USC Norris Comprehensive Cancer Center since 2007.
His primary research interests include the development of novel drugs for the treatment of solid tumors, especially gastrointestinal malignancies, the design and conduct of phase I and II clinical trials to test these drugs, and translational research focused on developing prognostic and predictive markers in patients with GI malignancies. Dr. El-Khoueiry has established a national reputation in the area of hepatobiliary cancers clinical research; he is the co-chair of the hepatobiliary cancers committee of the Southwest Oncology Group (SWOG) and a member of the National Cancer Institute (NCI) hepatobiliary cancers task force. He is the principal investigator on several clinical trials that are evaluating the role of novel drugs for the treatment of biliary and hepatocellular cancers.
As the phase I program director, Dr. El-Khoueiry has formed an experienced and highly skilled phase I clinical research team and established an efficient infrastructure for the conduct of high quality and innovative phase I studies. He has also worked with basic scientists at the USC Norris Comprehensive Cancer Center to design phase I studies to test novel compounds or novel combinations that had undergone pre-clinical testing at USC.
Dr. El-Khoueiry is frequently invited to give lectures nationally about gastrointestinal malignancies, particularly hepatobiliary cancers, and has a large number of peer-reviewed publications in his areas of research.

David Gerber, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Hematology/Oncology. He serves as Associate Director of Clinical Research for Simmons Cancer Center.
Originally from Chicago, Dr. Gerber holds a bachelor's degree in history from Yale University in New Haven, Connecticut, where he graduated cum laude. He earned his medical degree at Cornell University Medical College in New York, and completed his internship and residency in internal medicine at UT Southwestern, where he served as Chief Resident. He then received advanced training through a fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore.  
Board certified in internal medicine and medical oncology, Dr. Gerber joined the UT Southwestern faculty in 2007. 
Dr. Gerber is active in research related to lung cancer, including clinical trials. His research has generated more than 250 publications that he has authored or co-authored, including articles and book chapters. His studies have contributed to invitations to lecture both nationally and internationally.
He serves on several committees at UT Southwestern. Beyond the institution, he serves as Chair of the Clinical Trials Advisory Committee for the Cancer Prevention and Research Institute of Texas (CPRIT) and is a member of the National Comprehensive Cancer Network (NCCN) Oncology Research Program Investigator Steering Committee.
Dr. Gerber holds memberships in several professional organizations, and he has been honored with numerous awards, including being named a Best Doctor in Dallas by D Magazine during the years of 2011-2023.